Phase II study of nedaplatin plus irinotecan for stage III/IV squamous cell lung cancer (TORG0910)
Latest Information Update: 06 Nov 2017
Price :
$35 *
At a glance
- Drugs Irinotecan (Primary) ; Nedaplatin (Primary)
- Indications Lung cancer; Squamous cell cancer
- Focus Pharmacogenomic; Therapeutic Use
- 16 Mar 2013 New trial record